Pfizer Limited (NSE:PFIZER) — Market Cap & Net Worth
Market Cap & Net Worth: Pfizer Limited (PFIZER)
Pfizer Limited (NSE:PFIZER) has a market capitalization of $1.98 Billion (Rs183.10 Billion) as of September 19, 2026. Listed on the NSE stock exchange, this India-based company holds position #6256 globally and #283 in its home market, demonstrating a -4.04% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pfizer Limited's stock price Rs4002.40 by its total outstanding shares 45747732 (45.75 Million). Also see Pfizer Limited total assets for a full breakdown of the balance sheet.
Pfizer Limited Market Cap History: 2015 to 2026
Pfizer Limited's market capitalization history from 2015 to 2026. Data shows growth from $1.01 Billion to $1.98 Billion (5.81% CAGR). Also see Pfizer Limited cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Pfizer Limited is a constituent of 5 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY 500
NIFTY500
|
$3.08 Trillion | 0.06% | #251 of 500 |
|
NIFTY DIVIDEND OPPORTUNITIES 50
NIFTYDVOP
|
$733.41 Billion | 0.27% | #35 of 49 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$1.15 Trillion | 0.17% | #163 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.18 Trillion | 0.06% | #246 of 750 |
|
NIFTY SMALLCAP 250
NISM250
|
$411.67 Billion | 0.48% | #70 of 250 |
Weight: Pfizer Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pfizer Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pfizer Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Pfizer Limited stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.08x
Pfizer Limited's market cap is 0.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.27x
Pfizer Limited's market cap is 0.27 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $908.14 Million | $19.66 Billion | $3.37 Billion | 0.05x | 0.27x |
| 2018 | $1.26 Billion | $19.69 Billion | $3.60 Billion | 0.06x | 0.35x |
| 2019 | $1.88 Billion | $20.82 Billion | $4.29 Billion | 0.09x | 0.44x |
| 2020 | $2.44 Billion | $21.52 Billion | $5.09 Billion | 0.11x | 0.48x |
| 2021 | $2.43 Billion | $22.40 Billion | $4.98 Billion | 0.11x | 0.49x |
| 2022 | $2.16 Billion | $26.11 Billion | $6.13 Billion | 0.08x | 0.35x |
| 2023 | $2.10 Billion | $24.25 Billion | $6.24 Billion | 0.09x | 0.34x |
| 2024 | $2.61 Billion | $21.93 Billion | $5.51 Billion | 0.12x | 0.47x |
| 2025 | $2.47 Billion | $22.81 Billion | $7.68 Billion | 0.11x | 0.32x |
| 2026 | $1.98 Billion | $25.20 Billion | $7.22 Billion | 0.08x | 0.27x |
Competitor Companies of PFIZER by Market Capitalization
Companies near Pfizer Limited in the global market cap rankings as of September 19, 2026. Review PFIZER tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Pfizer Limited by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $1.03 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #45 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $1.03 Trillion | $1152.93 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $269.99 |
| #45 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $263.96 |
Pfizer Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Pfizer Limited's market cap moved from $1.01 Billion to $ 1.98 Billion, with a yearly change of 5.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs1.98 Billion | -19.75% |
| 2025 | Rs2.47 Billion | -5.56% |
| 2024 | Rs2.61 Billion | +24.46% |
| 2023 | Rs2.10 Billion | -2.83% |
| 2022 | Rs2.16 Billion | -10.97% |
| 2021 | Rs2.43 Billion | -0.50% |
| 2020 | Rs2.44 Billion | +29.47% |
| 2019 | Rs1.88 Billion | +49.11% |
| 2018 | Rs1.26 Billion | +39.11% |
| 2017 | Rs908.14 Million | +15.38% |
| 2016 | Rs787.11 Million | -22.04% |
| 2015 | Rs1.01 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Pfizer Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.98 Billion USD |
| MoneyControl | $1.98 Billion USD |
| MarketWatch | $1.98 Billion USD |
| marketcap.company | $1.98 Billion USD |
| Reuters | $1.98 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pfizer Limited
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers therapy area and products, such as vaccines, injectables and anti-infectives, inflammation and immunology, and internal medicine for cardiovascular care, oncology, respiratory, multivitamins and multimineral, neuroscience, women's health, gastroenterolog… Read more